Assessment of prognostic risk of death in patients with multiple myeloma based on CD184 and CD269: A retrospective analysis
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: This study aimed to analyze the expressions of CD184 and CD269 in patients with newly diagnosed multiple myeloma (MM) in China and explored their potential association with prognosis. Methods: This retrospective study recruited 100 patients with MM and 113 healthy controls who attended Beijing Chaoyang Hospital Shijingshan District between June 2020 and December 2023. The association between CD184 and CD269 expression and patient survival outcomes was assessed using univariable and multivariable Cox proportional hazards regression analyses, alongside Kaplan-Meier survival curves. Results: Both CD184 and CD269 mRNA were elevated in MM patients compared to controls (P<0.05). By qualitative analysis, it was seen that both CD184+ and CD269 patients had a reduced prognostic overall survival (OS) (P<0.05). Similarly, detection of CD184 and CD269 expression was effective in predicting prognostic mortality in patients. Conclusions: CD184 and CD269 may serve as valuable prognostic markers in MM patients.
Source: Journal of Medical Biochemistry
DOI: 10.5937/jomb0-56987
Authors: Hong Chen, Yuan Zhao, Zhiyu Zhang, Yan Xie, Mulan Jin
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4409440658